SCHEMBL3310503

SCHEMBL3310503

COC(=O)C(O)=CC(=O)c1ccc(-c2ccc(F)cc2)s1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.55
RAB9A P51151 4/20 0.55
NPC1 O15118 4/20 0.55
ALDH1A1 P00352 3/20 0.55
HPGD P15428 3/20 0.55
SMN1; SMN2 Q16637 3/20 0.50
MAPT P10636 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
ESRRG P62508 6/20 0.46
PTPN2 P17706 1/20 0.46
PTPN11 Q06124 1/20 0.46
ESR1 P03372 3/20 0.44
ESR2 Q92731 2/20 0.44
POLB P06746 1/20 0.43
GLA P06280 1/20 0.43
GAA P10253 1/20 0.43
IKBKB O14920 1/20 0.41
LMNA P02545 1/20 0.41
ACKR3 P25106 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3310498 1.00 KDM4E (0.55) KDM4ERAB9ANPC1ALDH1A1HPGD
SCHEMBL3314006 0.88 ESRRG (0.49) KDM4ERAB9ANPC1ALDH1A1HPGD
SCHEMBL3314002 0.88 ESRRG (0.49) KDM4ERAB9ANPC1ALDH1A1HPGD
SCHEMBL3309423 0.87 IKBKB (0.51) KDM4ERAB9ANPC1ALDH1A1HPGD
SCHEMBL3305591 0.87 KDM4E (0.43) KDM4ERAB9ANPC1ALDH1A1HPGD
SCHEMBL3305595 0.87 KDM4E (0.43) KDM4ERAB9ANPC1ALDH1A1HPGD
SCHEMBL3309429 0.87 IKBKB (0.51) KDM4ERAB9ANPC1ALDH1A1HPGD
SCHEMBL3308374 0.87 KDM4E (0.59) KDM4ENPC1ALDH1A1HPGDSMN1; SMN2
SCHEMBL3308378 0.87 KDM4E (0.59) KDM4ENPC1ALDH1A1HPGDSMN1; SMN2
SCHEMBL3313111 0.86 HDAC6 (0.41) KDM4ERAB9ANPC1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140171444-A1 Inhibitors of Mycobacterium Tuberculosis Malate Synthase, Methods of Making and Uses Thereof THE TEXAS A&M UNIVERSITY SYSTEM (US) 2014-06-19 US claimed
US-20140171444-A1 Inhibitors of Mycobacterium Tuberculosis Malate Synthase, Methods of Making and Uses Thereof THE TEXAS A&M UNIVERSITY SYSTEM (US) 2014-06-19 US disclosed
US-8664255-B2 Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof THE TEXAS A&M UNIVERSITY SYSTEM (US) 2014-03-04 US disclosed
US-20100113477-A1 Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof TEXAS A&M UNIVERSITY SYSTEM, THE 2010-05-06 US disclosed
WO-2010047774-A2 INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS MALATE SYNTHASE, METHODS OF MARKING AND USES THEREOF THE TEXAS A & M UNIVERSITY SYSTEM (US) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113477-A1 Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof ME3, ME1, MDH1 KDM4E 1397/4885RAB9A 3609/4885NPC1 2680/4885
US-20140171444-A1 Inhibitors of Mycobacterium Tuberculosis Malate Synthase, Methods of Making and Uses Thereof ME3, ME1, MDH1 KDM4E 1397/4885RAB9A 3609/4885NPC1 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.